You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recessive dystrophic epidermolysis bullosa

Showing 1 - 25 of 382
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB Trial in Redwood City, Worcester (EB-101 Surgical

Not yet recruiting
  • Epidermolysis Bullosa
  • +2 more
  • EB-101 Surgical application of RDEB wounds
  • Redwood City, California
  • +1 more
Feb 13, 2023

Recessive Dystrophic Epidermolysis Bullosa Trial (Spincare matrix)

Not yet recruiting
  • Recessive Dystrophic Epidermolysis Bullosa
  • Spincare matrix
  • (no location specified)
Jul 12, 2023

Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, New York (PTR-01)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • Redwood City, California
  • +1 more
Nov 17, 2022

Recessive Dystrophic Epidermolysis Bullosa Trial in United States (FCX-007 (dabocemagene autoficel; see below for FCX-007

Active, not recruiting
  • Recessive Dystrophic Epidermolysis Bullosa
  • FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
  • Stanford, California
  • +4 more
Aug 10, 2022

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Worcester (EB-101)

Active, not recruiting
  • Epidermolysis Bullosa
  • Recessive Dystrophic Epidermolysis Bullosa
  • EB-101
  • Redwood City, California
  • +1 more
Apr 5, 2022

Artificial Intelligence Patient App for RDEB SCCs

Recruiting
  • Epidermolysis Bullosa Dystrophica
  • online survey
  • Chicago, Illinois
    Department of Dermatology, Northwestern University Feinberg Scho
May 3, 2023

Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma Trial in Salzburg (Rigosertib Oral Capsules / Rigosertib Intravenous)

Recruiting
  • Epidermolysis Bullosa Dystrophica
  • Squamous Cell Carcinoma
  • Rigosertib Oral Capsules / Rigosertib Intravenous
  • Salzburg, Austria
    EB House Austria/Dept. of Dermatology University Hospital
Nov 3, 2022

Participants Previously Treated With EB-101 for Treatment of

Enrolling by invitation
  • RDEB
  • EB-101
  • Redwood City, California
  • +1 more
Feb 1, 2023

Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa Trial in

Completed
  • Dystrophic Epidermolysis Bullosa
  • +2 more
  • Topical Beremagene Geperpavec
  • Placebo
  • Rancho Santa Margarita, California
  • +2 more
Aug 1, 2022

Recessive Dystrophic Epidermolysis Bullosa Trial in Salzburg (Genetically corrected cultured epidermal autograft (ATMP))

Terminated
  • Recessive Dystrophic Epidermolysis Bullosa
  • Genetically corrected cultured epidermal autograft (ATMP)
  • Salzburg, Austria
    EB House Austria, Department of Dermatology, Paracelsus Medical
Feb 15, 2022

Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Aurora (PTR-01)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • Redwood City, California
  • +1 more
Sep 14, 2021

Epidermolysis Bullosa Dystrophica, Recessive Trial in Stanford, Aurora (FCX-007)

Active, not recruiting
Has Results
  • Epidermolysis Bullosa Dystrophica, Recessive
  • FCX-007
  • Stanford, California
  • +1 more
Sep 30, 2021

Recessive Dystrophic Epidermolysis Bullosa Trial in Philadelphia (Rigosertib Sodium, Quality-of-Life Assessment)

Recruiting
  • Recessive Dystrophic Epidermolysis Bullosa
  • Rigosertib Sodium
  • Quality-of-Life Assessment
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Aug 31, 2021

Recessive Dystrophic Epidermolysis Bullosa Trial in Worldwide (allo-APZ2-EB)

Completed
  • Recessive Dystrophic Epidermolysis Bullosa
  • allo-APZ2-EB
  • Minneapolis, Minnesota
  • +5 more
Oct 6, 2022

Epidermolysis Bullosa Trial in Aurora, Chicago, New York (Palifermin, Fludarabine, Busulfan)

Terminated
  • Epidermolysis Bullosa
  • Aurora, Colorado
  • +2 more
Aug 13, 2021

Patients With Recessive Dystrophic Epidermolysis Bullosa

Recruiting
  • Epidermolysis Bullosa Dystrophica
    • Stanford, California
      Stanford University School of Medicine
    Mar 17, 2021

    Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Aurora, Philadelphia (PTR-01, Normal saline)

    Completed
    • Recessive Dystrophic Epidermolysis Bullosa
    • Redwood City, California
    • +2 more
    Mar 8, 2021

    Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa Trial in

    Recruiting
    • Dystrophic Epidermolysis Bullosa
    • +3 more
    • Open Label Topical Beremagene Geperpavec (B-VEC)
    • Rancho Santa Margarita, California
    • +5 more
    Jun 7, 2021

    Pain, Neuropathic, Itch, Epidermolysis Bullosa Trial in Toronto (Pregabalin)

    Recruiting
    • Pain, Neuropathic
    • +2 more
    • Toronto, Ontario, Canada
      The Hospital for Sick Children
    Jun 9, 2021

    Long-Term Follow-up Protocol

    Recruiting
    • Dystrophic Epidermolysis Bullosa
    • +2 more
      • Rancho Santa Margarita, California
      • +2 more
      Jun 7, 2021

      Recessive Dystrophic Epidermolysis Bullosa Trial in Los Angeles (Gentamicin)

      Unknown status
      • Recessive Dystrophic Epidermolysis Bullosa
      • Los Angeles, California
        University of Southern California
      Nov 2, 2020

      Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Trial in Stanford (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets)

      Active, not recruiting
      • Epidermolysis Bullosa Dystrophica
      • Epidermolysis Bullosa
      • LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
      • Stanford, California
        Stanford University School of Medicine
      Oct 23, 2020

      Recessive Dystrophic Epidermolysis Bullosa Trial in Seoul (Human Umbilical Cord Blood-derived Mesenchymal Stem Cells)

      Completed
      • Recessive Dystrophic Epidermolysis Bullosa
      • Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
      • Seoul, Korea, Republic of
        GangnamSeverance Hospital
      Aug 17, 2020

      Molecular Signatures of Cutaneous Squamous Cell Carcinoma During

      Not yet recruiting
      • Recessive Dystrophic Epidermolysis Bullosa
        • (no location specified)
        Feb 24, 2020

        Dystrophic Epidermolysis Bullosa Trial in Stanford (Topical beremagene geperpavec)

        Completed
        Has Results
        • Dystrophic Epidermolysis Bullosa
        • Topical beremagene geperpavec
        • Placebo gel
        • Stanford, California
          Stanford University
        Jan 30, 2023